| References: |
The inhibition of the interaction of PD-Ll with PD-1 is thus a viable and promising therapeutic target for the treatment of cancer
and/or chronic infections. The invention in this patent application presents compounds with activities as inhibitors of the
PD-1/PD-Ll protein/protein interactions.For the detailed information of PD-1/PD-L1 inhibitor 2, the solubility of PD-1/PD-L1 inhibitor 2 in water, the solubility of PD-1/PD-L1 inhibitor 2 in DMSO, the solubility of PD-1/PD-L1 inhibitor 2 in PBS buffer, the animal experiment (test) of PD-1/PD-L1 inhibitor 2, the cell expriment (test) of PD-1/PD-L1 inhibitor 2, the in vivo, in vitro and clinical trial test of PD-1/PD-L1 inhibitor 2, the EC50, IC50,and affinity,of PD-1/PD-L1 inhibitor 2, For the detailed information of PD-1/PD-L1 inhibitor 2, the solubility of PD-1/PD-L1 inhibitor 2 in water, the solubility of PD-1/PD-L1 inhibitor 2 in DMSO, the solubility of PD-1/PD-L1 inhibitor 2 in PBS buffer, the animal experiment (test) of PD-1/PD-L1 inhibitor 2, the cell expriment (test) of PD-1/PD-L1 inhibitor 2, the in vivo, in vitro and clinical trial test of PD-1/PD-L1 inhibitor 2, the EC50, IC50,and affinity,of PD-1/PD-L1 inhibitor 2, Please contact DC Chemicals. |
